Firstly, in an effort to investigate the impact of neddylation modification on the therapeutic effectiveness of BCR::ABL1-targeting TKIs in CML, we treated K562 CML cells with three different TKIs, including imatinib (the first-generation TKI), nilotinib (a second-generation TKI), and ponatinib (a third-generation TKI), which are designed to target BCR::ABL1 carrying different mutation sites. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.